Evidence map›Paper›PMID 40523620›Full record

ReviewThe Journal of biological chemistry2025

Structural biology of Parkinson's disease-associated leucine-rich repeat kinase 2 (LRRK2).

Andres E Leschziner

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Journal of biological chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. LRRK2: Molecular Mechanisms in Parkinson's Disease.International journal of molecular sciences · 2026
    Review
  2. Article
  3. Elucidating the molecular interplay between LRRK2 and Rab GTPases.bioRxiv : the preprint server for biology · 2026
    Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Andres E LeschzinerDepartment of Cellular and Molecular Medicine, School of Medicine, University of California San Diego, La Jolla, California, USA; Department of Molecular Biology, School of Biological Sciences, University of California San Diego, La Jolla, California, USA; Aligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, Maryland, USA. Electronic address: ale4009@med.cornell.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Leucine-rich repeat kinase 2 (LRRK2) has gone, in a little over 2 decades, from a novel gene linked to cases of Parkinson's disease (PD) in one family to being the main actionable target for PD therapeutics, with several clinical trials targeting it currently underway. While much remains to be understood about LRRK2-including, chiefly, why its increased activity is linked to PD-much has also been learned. One of the areas where our knowledge has increased exponentially in a very short time is the structural biology of LRRK2. The goal of this review is to provide a survey of the current landscape of LRRK2 structural biology with an emphasis on the functional insights that structures have provided.

Indexed as

Leucine-Rich Repeat Serine-Threonine Protein Kinase-2Parkinson DiseaseAnimalsHumansLeucine-Rich Repeat Serine-Threonine Protein Kinase-2LRRK2 protein, humancryo-EMGTPasekinaseLRRK2Parkinson's diseasestructural biology

Identifiers

PMID40523620
PMCPMC12337188

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.